2025-08-25 - Analysis Report
Okay, here's a report analyzing Transmedics Group Inc. (TMDX), incorporating the provided data.

## Transmedics Group Inc. (TMDX) Analysis

**Transmedics Group Inc. (TMDX) is a medical technology company focused on preserving and assessing organs for transplant.**

### 1. Performance vs. S&P 500 (VOO)

*   **TMDX Cumulative Return:** 231.76%
*   **VOO Cumulative Return:** 38.83%
*   **Absolute Divergence (Current):** 166.6
*   **Relative Divergence:** 64.0

**Analysis:**

TMDX has significantly outperformed the S&P 500 (VOO) over the analyzed period.  The current absolute divergence is 166.6. The relative divergence of 64.0 indicates that the current divergence is positioned in the upper-middle range of its historical divergence range compared to VOO.  This suggests that TMDX's outperformance, while significant, may not be at its absolute peak relative to the S&P 500.

**Alpha/Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha   | Beta  | Cap(B) |
| :----------- | :------ | :------ | :------ | :---- | :----- |
| 2019-2021  | -4.0%   | 63.4% | -5.0%  | 0.8   | 0.7    |
| 2020-2022  | 140.0%  | 68.3% | 150.0% | 0.2   | 2.1    |
| 2021-2023  | 95.0%   | 69.4% | 86.0%  | 0.1   | 2.7    |
| 2022-2024  | 147.0%  | 82.8% | 117.0% | -0.0   | 2.1    |
| 2023-2025  | 113.0%  | 82.8% | 68.0%  | 0.0   | 4.1    |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** The CAGR varies significantly, reflecting periods of both negative and strong growth.
*   **MDD (Maximum Drawdown):**  High MDD values (63.4% - 82.8%) indicate significant volatility and potential risk.
*   **Alpha:** Consistently positive Alpha values, especially in recent periods, suggest TMDX has outperformed its benchmark even after accounting for market risk.
*   **Beta:** Low Beta values (close to 0 or even negative in 2022-2024) indicate that TMDX's price is not highly correlated with the overall market.  In 2023-2025 beta is 4.1. It could be said that TMDX's price is highly correlated with the overall market.
*   **Cap(B):** Market capitalization has increased from 0.7B to 4.1B from 2019 to 2025

### 2. Recent Stock Price Action

*   **Current Price:** 119.85
*   **Previous Close:** 118.81
*   **Change:** 0.88
*   **5-day Moving Average:** 121.77
*   **20-day Moving Average:** 120.87
*   **60-day Moving Average:** 124.19

**Analysis:**

The stock price experienced a slight increase in the last trading session. The current price is below the 5-day, 20-day, and 60-day moving averages, suggesting a potential short-term downtrend or consolidation phase.

### 3. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.3377 (Low Risk)
*   **RSI:** 40.56
*   **PPO:** -0.23
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.33)
*   **Recent (20-day) Relative Divergence Change:** -7.2 (Negative - Short-term decline)
*   **Expected Return (%):** 58.9%

**Analysis:**

*   The MRI indicates a low-risk environment.
*   The RSI of 40.56 suggests the stock is approaching oversold territory, potentially indicating a buying opportunity.
*   The negative PPO indicates a potential downward trend in price momentum.
*   The Hybrid Signal suggests a "Buy" signal, but with caution due to the MRI. It recommends buying 80% of cash.
*   The negative change in relative divergence over the past 20 days confirms a recent short-term decline in performance compared to the S&P 500.
*   The expected return of 58.9% suggests a potentially high return over the long term (2+ years) compared to the S&P 500, assuming a buy-and-hold strategy.
*   The change of 0.88 can be considered not high

### 4. Recent News & Significant Events

*   **[2025-08-22]:** Major business developments, regulatory changes, or market events.
*   **[2025-08-24]:** Analyst discussions on performance and outlook.
*   **[2025-08-25]:** Notable stock volatility.
*   **[2025-08-21]:** Market experts highlight risks and opportunities.

**Analysis:**

The news suggests recent activity and volatility surrounding TMDX. Investors should closely monitor news sources and company announcements to stay informed about potential catalysts influencing the stock price.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 예상 EPS |
| :--------- | :---- | :------- |
| 2025-07-30 | 0.92  | 0.48     |
| 2025-05-08 | 0.7   | 0.29     |
| 2025-02-27 | 0.19  | 0.22     |
| 2024-10-28 | 0.12  | 0.29     |
| 2024-07-31 | 0.35  | 0.21     |

**Analysis:**

TMDX has consistently beaten EPS estimates in recent quarters, particularly in the most recent two quarters. This suggests strong financial performance and positive market sentiment. The trend suggests strong financial health.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
| :--------- | :------ | :------------ |
| 2025-06-30 | $0.16B | 61.38%        |
| 2025-03-31 | $0.14B | 61.47%        |
| 2024-12-31 | $0.12B | 59.21%        |
| 2024-09-30 | $0.11B | 55.94%        |
| 2024-06-30 | $0.11B | 60.59%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE     |
| :--------- | :------- | :------ |
| 2025-06-30 | $0.32B | 10.97% |
| 2025-03-31 | $0.27B | 9.64%  |
| 2024-12-31 | $0.23B | 3.00%  |
| 2024-09-30 | $0.21B | 2.01%  |
| 2024-06-30 | $0.19B | 6.42%  |

**Analysis:**

*   **Revenue:** Revenue has been steadily increasing over the past year.
*   **Profit Margin:** Profit margins are very high and have remained relatively consistent, indicating strong pricing power or efficient operations.
*   **Equity:** Total equity has been increasing, demonstrating financial strength.
*   **ROE (Return on Equity):** ROE has significantly increased in the most recent quarters, indicating improved profitability relative to equity.

### 7. 종합적인 분석 (Overall Analysis)

TMDX exhibits strong growth potential and has significantly outperformed the S&P 500. Recent earnings beats, increasing revenue, high profit margins, and increasing ROE indicate robust financial health. While the stock price is currently below its short-term moving averages and the RSI is approaching oversold territory, the long-term outlook remains positive, with a high expected return. The low MRI suggests a relatively stable market environment for the stock. Recent news points to significant events and volatility, warranting careful monitoring. The Hybrid Signal provides a cautious "Buy" signal.

**Recommendation:** Given the strong fundamentals and positive outlook, a buy-and-hold strategy with careful monitoring of news and market events may be appropriate. Consider the Hybrid Signal's recommendation to buy with a portion of available cash. The high MDD requires to keep your mind in a long-term perspective.
